LONDON, Nov 16 (Reuters) - GlaxoSmithKline PLC:
* Announces worldwide option, licensing agreement for a nicotine conjugate
candidate vaccine, NicVAX, with Nabi Biopharmaceuticals
* Says upfront and potential consideration of over $500 million for Nabi
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Announces worldwide option, licensing agreement for a nicotine conjugate
candidate vaccine, NicVAX, with Nabi Biopharmaceuticals
* Says upfront and potential consideration of over $500 million for Nabi
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.